通痹Ⅰ号治疗类风湿关节炎疗效观察

Clinical observation of Tongbi Ⅰ in the treatment of rheumatoid arthritis

关键词:  类风湿关节炎  痹病  中医药治疗  通痹Ⅰ号

Key words:  rheumatoid arthritis  arthralgia syndrome  traditional Chinese medicine treatment  Tongbi Ⅰ

摘要:

[目的] 观察通痹Ⅰ号治疗类风湿关节炎的临床疗效及安全性。[方法] 纳入2018年2月-2019年10月上海中医药大学附属光华医院门诊诊治的80例类风湿关节炎患者，按照随机数字表法分为对照组和试验组，每组40例。对照组予甲氨蝶呤片+美洛昔康片治疗，试验组予通痹Ⅰ号+甲氨蝶呤片+美洛昔康片治疗，两组患者均以12周为1个疗程。比较两组患者治疗前后晨僵时间、关节压痛数、关节肿胀数、疼痛视觉模拟评分法（VAS）评分、28处关节疾病活动度评分（DAS28）-红细胞沉降率（ESR）、DAS28-C反应蛋白（CRP）、ESR、CRP及不良反应发生情况，评价临床疗效。[结果] 两组患者治疗后晨僵时间、关节压痛数、关节肿胀数、疼痛VAS评分、DAS28-ESR、DAS28-CRP、ESR、CRP均低于治疗前，差异有统计学意义（P<0.05）；试验组晨僵时间、关节压痛数、关节肿胀数、疼痛VAS评分、DAS28-ESR、DAS28-CRP指标改善情况均明显优于对照组，差异有统计学意义（P<0.05），ESR、CRP改善情况比较差异无统计学意义（P>0.05）。两组均未发生明显不良反应。[结论] 联合应用通痹Ⅰ号治疗类风湿关节炎疗效确切，可明显缓解患者临床症状及体征，疗效优于单用甲氨蝶呤片+美洛昔康片，且无明显药物不良反应。

Abstract:

[Objective] To observe the clinical efficacy and safety of Tongbi I in the treatment of rheumatoid arthritis.[Methods] A total of 80 patients with rheumatoid arthritis who were included in the outpatient department of Shanghai GuangHua Hospital from February 2018 to October 2019 were divided into the control group and the observationgroup according to the random number table method, with 40 patients in each group. The control group was treated with methotrexate tablets and meloxicam tablets, while the observation group was treated with Tongbi I, methotrexate tablets and meloxicam tablets. Patients in both groups were given a course of treatment for 12 weeks. The time of morning stiffness, number of joint tenderness, number of joint swelling, visual analogue scale (VAS), DAS28-ESR, DAS28-CRP, ESR, CRP and adverse reactions before and after treatment were compared between two groups to evaluate the clinical efficacy.[Results] After treatment, morning stiffness time, number of joint tenderness, number of joint swelling, VAS score, DAS28-ESR, DAS28-CRP, ESR and CRP of the two groups were all lower than those before treatment, and the differences were statistically significant (P<0.05). The improvement of morning stiffness time, number of joint tenderness, number of joint swelling, VAS score, DAS28-ESR and DAS28-CRP in the observation group was significantly better than that in the control group, and the difference was statistically significant(P<0.05), while the improvement of ESR and CRP was not statistically significant(P>0.05). No significant adverse reactions occurred in two groups.[Conclusion] TongbiⅠcombined treatment of rheumatoid arthritis is effective, which can significantly alleviate the clinical signs and symptoms of patients, the efficacy is better than the single methotrexate tablets, and no obvious adverse drug reactions.